Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain
CompletedPhase 3NCT02920528
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This is a prospective, randomized controlled trial which will be conducted to determine whether sub-dissociative dose ketamine (SDDK) can improve pain control in subjects with chronic pain syndrome presenting to the emergency department with exacerbation of their chronic pain. The investigators also aim to determine whether use of SDDK can reduce the amount of subsequent opioid pain medications required for adequate pain relief in this population.
Study details
- Official title
- Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain: A Randomized Controlled Trial
- Conditions
- Interventions
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Collaborators
- United States Air Force Research Laboratory
- Start date
- 2017-05-01
- Primary completion
- 2018-06-22
- Sex
- All
- Age range
- from 18 Years
- Healthy volunteers
- true
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * All adult subjects over the age of 18 with chronic pain\* presenting to the emergency department with exacerbation of their chronic pain as their primary complaint * Subjects who are willing and able to provide informed consent. \*Chronic pain defined as greater \> 3 months of symptoms and an initial VAS pain score \> 70 Exclusion Criteria: * History of overt psychosis, severe hypertension as defined by Systolic Blood Pressure \> 180 mm Hg or Diastolic Blood Pressure \>110 mm Hg, unstable angina, Coronary Artery Disease, Congestive Heart Failure, porphyrias, thyroid disease, seizure disorder, inability to provide informed consent: dementia, non-English/Spanish speakers, subjects in custody, suicidal, or clinically intoxicated.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02920528